Geode Capital Management’s Regenxbio RGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$14.9M Buy
1,241,296
+103,798
+9% +$861K ﹤0.01% 2319
2026
Q1
$9.53M Sell
1,137,498
-7,708
-0.7% -$81K ﹤0.01% 2408
2025
Q4
$16.5M Buy
1,145,206
+19,658
+2% +$245K ﹤0.01% 2115
2025
Q3
$10.9M Sell
1,125,548
-2,973
-0.3% -$26.3K ﹤0.01% 2374
2025
Q2
$9.27M Buy
1,128,521
+21,575
+2% +$181K ﹤0.01% 2417
2025
Q1
$7.92M Buy
1,106,946
+12,721
+1% +$94.6K ﹤0.01% 2429
2024
Q4
$8.46M Buy
1,094,225
+5,574
+0.5% +$52.3K ﹤0.01% 2472
2024
Q3
$11.4M Buy
1,088,651
+44,037
+4% +$537K ﹤0.01% 2299
2024
Q2
$12.2M Buy
1,044,614
+94,063
+10% +$1.46M ﹤0.01% 2205
2024
Q1
$20M Buy
950,551
+20,879
+2% +$372K ﹤0.01% 1930
2023
Q4
$16.7M Buy
929,672
+46,526
+5% +$820K ﹤0.01% 2023
2023
Q3
$14.5M Buy
883,146
+69,617
+9% +$1.26M ﹤0.01% 2027
2023
Q2
$16.3M Buy
813,529
+52,732
+7% +$1.02M ﹤0.01% 1994
2023
Q1
$14.4M Buy
760,797
+27,552
+4% +$610K ﹤0.01% 2017
2022
Q4
$16.6M Buy
733,245
+25,672
+4% +$580K ﹤0.01% 1899
2022
Q3
$18.7M Buy
707,573
+7,805
+1% +$232K ﹤0.01% 1774
2022
Q2
$17.3M Buy
699,768
+14,129
+2% +$353K ﹤0.01% 1861
2022
Q1
$22.8M Buy
685,639
+17,786
+3% +$494K ﹤0.01% 1810
2021
Q4
$21.8M Buy
667,853
+2,434
+0.4% +$82.9K ﹤0.01% 1898
2021
Q3
$27.9M Buy
665,419
+2,711
+0.4% +$97.5K ﹤0.01% 1730
2021
Q2
$25.7M Buy
662,708
+34,771
+6% +$1.24M ﹤0.01% 1793
2021
Q1
$21.4M Buy
627,937
+104,749
+20% +$4.47M ﹤0.01% 1840
2020
Q4
$23.7M Buy
523,188
+29,792
+6% +$1.04M ﹤0.01% 1608
2020
Q3
$13.6M Sell
493,396
-17,282
-3% -$563K ﹤0.01% 1777
2020
Q2
$18.8M Buy
510,678
+20,468
+4% +$763K ﹤0.01% 1553
2020
Q1
$15.9M Buy
490,210
+28,988
+6% +$1.21M ﹤0.01% 1456
2019
Q4
$18.9M Buy
461,222
+3,129
+0.7% +$124K ﹤0.01% 1600
2019
Q3
$16.3M Buy
458,093
+25,802
+6% +$1.05M ﹤0.01% 1616
2019
Q2
$22.2M Buy
432,291
+24,917
+6% +$1.24M 0.01% 1417
2019
Q1
$23.3M Buy
407,374
+28,586
+8% +$1.42M 0.01% 1312
2018
Q4
$15.9M Buy
378,788
+40,159
+12% +$2.36M ﹤0.01% 1447
2018
Q3
$25.6M Buy
338,629
+41,462
+14% +$2.99M 0.01% 1228
2018
Q2
$21.3M Buy
297,167
+36,755
+14% +$1.76M 0.01% 1300
2018
Q1
$7.77M Buy
260,412
+12,084
+5% +$352K ﹤0.01% 1949
2017
Q4
$8.26M Buy
248,328
+2,506
+1% +$75.5K ﹤0.01% 1878
2017
Q3
$8.1M Buy
245,822
+15,915
+7% +$358K ﹤0.01% 1873
2017
Q2
$4.54M Buy
229,907
+58,561
+34% +$1.13M ﹤0.01% 2213
2017
Q1
$3.31M Buy
171,346
+5,949
+4% +$115K ﹤0.01% 2366
2016
Q4
$3.07M Buy
165,397
+4,668
+3% +$89.2K ﹤0.01% 2378
2016
Q3
$2.25M Buy
160,729
+90,158
+128% +$995K ﹤0.01% 2490
2016
Q2
$564K Buy
70,571
+13,429
+24% +$149K ﹤0.01% 3178
2016
Q1
$617K Buy
57,142
+8,255
+17% +$106K ﹤0.01% 3115
2015
Q4
$811K Buy
+48,887
New +$970K ﹤0.01% 3023

Other funds holding RGNX

Geode Capital Management's RGNX Position: Q2 2026 in Review

Geode Capital Management increased its Regenxbio (RGNX) stake by 9.1% in Q2 2026, buying an estimated $861K and bringing the position to 1,241,296 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Geode Capital Management first reported a position in RGNX in Q4 2015 and has held it in 43 quarters since. The position peaked at $27.9M in Q3 2021. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • Geode Capital Management held 1,241,296 shares of Regenxbio worth $14.9M as of Q2 2026.
  • Geode Capital Management bought 103,798 Regenxbio shares in Q2 2026, an estimated $861K.
  • Regenxbio made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2319 holding.
  • Geode Capital Management first reported a position in Regenxbio in Q4 2015 and has held it in 43 quarters since.
  • Geode Capital Management's Regenxbio position peaked at $27.9M in Q3 2021.
  • 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.